Decoding The Immune System To Speed Vaccine/Immunotherapy R&D
The Human Vaccines Project, a consortium of biopharmaceutical companies, academic institutions and nonprofit product developers, is aiming to conduct numerous small, focused trials in an effort to decode the human immune system to improve the way vaccines and immunotherapies are developed.
You may also be interested in...
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
With the successes in the past few weeks of vaccines for Ebola and malaria – both being described as game-changers for the diseases they are intended to prevent – the industry and researchers have much to celebrate.
When the Human Genome Project officially got underway in 1990, the notion of consortium-based biomedical research was scary to many scientists, said Dr Eric Green, director of the National Human Genome Research Institute at the National Institutes of Health (NIH).